Improving quality of life through innovations in urology.
Improving quality of life through innovations in urology.
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
The latest posts and articles
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Nov. 5, 2019-- Urovant Sciences (Nasdaq: […]
Read Latest Post
Sumitomo Dainippon Pharma has committed to provide an initial $200 million , low-interest, […]
Read Latest Post
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Oct. 29, 2019-- Urovant Sciences […]
Read Latest Post
Copyright 2018 © All Rights Reserved